UGT2A3

Across TCGA pan-cancer cohorts, UGT2A3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UGT2A3 data layer compared with 17 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UGT2A3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated UGT2A3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where UGT2A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.906	0.789	<.001	93	view →
CCRCC	DFS	Quartile	III,IV	0.773	0.249	<.001	72	view →
COAD	DFS	Tertile	III,IV	1.000	0.831	.049	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

UGT2A3–PDAC (OS)

Open the PDAC breakdown →